pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccines 119

Vaccines Immunity Immunization 119

European Pharmaceutical Review

NOVEMBER 1, 2023

adapted COVID-19 vaccine, developed by Novavax for this autumn and winter season. The vaccine, known as Nuvaxovid XBB.1.5, In its decision to recommend the authorisation, the EMA’s human medicines committee (CHMP) assessed laboratory data showing that the adapted vaccine is able to trigger an adequate immune response against XBB.1.5.

Vaccines 105

Vaccines Immunity Immunization 105

Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

pharmaphorum

SEPTEMBER 4, 2020

Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction.

Vaccines 106

Vaccines Immunity Immunization 106

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. This is an additional ingredient designed to trigger a stronger immune response.

Vaccines 98

Vaccines Immunity Immunization 98

Express Pharma

AUGUST 31, 2023

” AstraZeneca said the deal would support investigational mRNA vaccines early in its pipeline, but the companies have declined to provide any further details. .” ” AstraZeneca said the deal would support investigational mRNA vaccines early in its pipeline, but the companies have declined to provide any further details.

Vaccines 114

Vaccines Immunity Immunization 114

pharmaphorum

DECEMBER 17, 2020

Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR).

Vaccines 105

Vaccines Immunity Immunization Hospitals 105

pharmaphorum

NOVEMBER 25, 2021

A new variant of COVID-19 identified in Botswana with dozens of mutations is being watched closely, amid fears it could be resistant to the effect of currently-used vaccines. — Tom Peacock (@PeacockFlu) November 23, 2021. The post New COVID variant ‘may sidestep vaccine protection’ appeared first on.

Vaccines 116

Vaccines Immunity Immunization 116

pharmaphorum

SEPTEMBER 27, 2022

Ben Hargreaves finds that the next step to enhance these treatments further could be to find synergies with emerging therapies employing similar modes of action, such as therapeutic cancer vaccines. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines.

Vaccines 97

Vaccines Immunity Immunization 97

Express Pharma

AUGUST 23, 2023

The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.

Vaccines 98

Vaccines Documentation Immunity Immunization 98

pharmaphorum

JULY 21, 2022

GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) infections. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on. . ” He said.

Vaccines 105

Vaccines Immunity Immunization 105

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunity Immunization Documentation 98

pharmaphorum

AUGUST 12, 2021

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. The Johnson & Johnson vaccine is also supplied on a no-profit basis. Pricing slammed.

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

MARCH 18, 2021

An EMA advisory committee’s review of AstraZeneca’s COVID-19 has concluded that there is no increase in the overall risk of blood clots with this vaccine. And because the vaccine is effective in preventing COVID-19 disease – which in itself is a cause of blood clots – it “likely reduces the risk of thrombotic events overall.”.

Vaccines 105

Vaccines Immunity Immunization 105

European Pharmaceutical Review

AUGUST 30, 2022

It has highlighted the value of cutting-edge technologies, such as messenger RNA (mRNA) vaccines, and reinforced the industry’s understanding of the power of collaboration, including with contract partners such as contract development and manufacturing organisations (CDMOs). The rise of the nasal vaccine route.

Vaccines 119

Vaccines Immunity Immunization 119

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 97

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 97

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunity Immunization 80

NY Times

AUGUST 25, 2021

Congress appropriated $16 billion to ramp up Covid-19 countermeasures, but a new report found that the Biden administration had spent very little of it on expanding vaccine manufacturing capacity.

Vaccines 96

Vaccines Immunity Immunization 96

Eye on FDA

NOVEMBER 17, 2020

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

Communication 81

Communication Vaccines HIPAA Documentation 81

pharmaphorum

JANUARY 26, 2021

The EU has hit back at AstraZeneca’s plan to provide fewer doses of its COVID-19 vaccine than expected, saying it wants to see exactly where supplies have been delivered so far. . EU Member States are united: vaccine developers have societal and contractual responsibilities they need to uphold.

Vaccines 69

Vaccines Immunity Immunization 69

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. million in 2021 to 0.54 per cent from 0.43

Vaccines 52

Vaccines Immunity Immunization 52

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.

Vaccines 64

Vaccines Immunity Immunization 64

pharmaphorum

MARCH 17, 2022

Alnylam claims it is owed a slice of the massive revenues booked by Pfizer and Moderna for their mRNA-based COVID-19 vaccines, because they are both infringing patents its holds on a delivery technology. Moderna meanwhile booked around $18 billion from SpikeVax in 2021 and is forecasting around the same again this year.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot. GlaxoSmithKline has agreed a $3.3

Vaccines 52

Vaccines Immunity Immunization 52

Pharmaceutical Technology

MAY 4, 2023

After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).

Vaccines 64

Vaccines Communication Immunity Immunization 64

Quality Matters

MAY 24, 2023

World Vaccine Congress 2023: Spotlight shines on mRNA and viral vectored technology platforms Interest in innovative vaccines that use messenger ribonucleic acid (mRNA) and viral vectored technologies was among the key draws at this year’s World Vaccine Congress (WVC) on April 3-6 in Washington, D.C.

Vaccines 52

Vaccines Documentation Immunity Immunization 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59

pharmaphorum

JANUARY 11, 2022

What HCPs think about mandatory vaccination. The practice of making vaccinations mandatory within a population has always been controversial. Historically, the first example of this was during the smallpox epidemic in the 1800s , when some European countries attempted to make vaccination against the disease compulsory.

Vaccines 98

Vaccines Immunity Immunization Hospitals 98

Express Pharma

JUNE 26, 2024

The success of the COVID-19 mRNA vaccines highlighted the major advantages of utilising mRNA technology in vaccine development. Consequently, the FDA has awarded a rising number of review designations to mRNA vaccines in recent years. Implementation of these vaccines is estimated to have prevented 14.4

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.

Vaccines 97

Vaccines Immunity Immunization 97

Express Pharma

JULY 7, 2023

Researchers and clinicians from the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust are part of the ongoing OCTAVE (Observational Cohort Trial-T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2) trial, which is led by the Universities of Glasgow, Birmingham and Oxford and a consortium of leading UK institutions.

Immunity 104

Immunity Immunization Vaccines Hospitals 104

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. 1 WHO’s analysis was stark.

Vaccines 115

Vaccines Immunity Immunization Drug Development 115

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117

Vaccines Immunity Immunization 117

European Pharmaceutical Review

FEBRUARY 14, 2023

Recently there have been several key advances in the clinical development of messenger RNA (mRNA) vaccines, including vaccines for RSV and a personalised cancer vaccine. Sarah Bundra, Pharmaceutical Analyst at GlobalData also warned about patient safety: “introducing mRNA carries the risk of activating the immune system.”

Vaccines 105

Vaccines Immunity Immunization 105

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunity Immunization 111

Express Pharma

FEBRUARY 1, 2024

Phase 3 trial data results of The R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India, leveraging Novavax’s Matrix-M adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. No other vaccine has reported over 55 per cent efficacy in the same age group.

Vaccines 105

Vaccines Immunity Immunization 105